Clinical Trials Logo

Ulcer clinical trials

View clinical trials related to Ulcer.

Filter by:

NCT ID: NCT06260163 Recruiting - Colitis, Ulcerative Clinical Trials

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

QUASAR Jr
Start date: January 19, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.

NCT ID: NCT06257875 Recruiting - Ulcerative Colitis Clinical Trials

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Start date: March 23, 2024
Phase: Phase 2
Study type: Interventional

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult subjects with UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of UC. Participants are placed in groups called treatment arms. Each group receives a different treatment. In the Induction Period, participants will be randomized into 1 of 3 arms receiving lutikizumab Dose 1, lutikizumab Dose 2, or adalimumab. In the Maintenance Period, participants who responded to lutikizumab will be randomized into 1 of 2 arms of lutikizumab maintenance and participants who responded to adalimumab will continue to receive adalimumab. All participants who did not achieve clinical response per modified Mayo Score at the end of the Induction period will receive open label lutikizumab. Around 200 adult participants with UC will be enrolled at approximately 280 sites worldwide. In the Induction Period, participants will be randomized to receive intravenous (IV) and subcutaneous (SC) lutikizumab or SC adalimumab for 12 weeks. At the 12 week mark, participants who are on lutikizumab who have responded to treatment will be re-randomized to receive SC lutikizumab at different intervals until Week 52. Participants who are on adalimumab who are responding to treatment will continue to receive adalimumab until Week 52. Participants who do not respond to treatment will receive open-label SC lutikizumab until Week 52. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

NCT ID: NCT06255288 Recruiting - Venous Leg Ulcer Clinical Trials

Time to Heal (Wound, Healing, Dialogue, Nutrition)

SNAK
Start date: January 23, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to examine the feasibility, acceptability, fidelity, and outcome of a nurse-led nutritional intervention for patients with leg ulcers in a outpatient clinics. The intervention consists of a structured dialogue and patient information on key lifestyle behaviours to improve wound healing. Furthermore, the intervention includes protein supplement.

NCT ID: NCT06254950 Recruiting - Ulcerative Colitis Clinical Trials

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Start date: March 29, 2024
Phase: Phase 2
Study type: Interventional

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.

NCT ID: NCT06236750 Recruiting - Diabetic Foot Ulcer Clinical Trials

Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds

Start date: August 4, 2023
Phase: N/A
Study type: Interventional

The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.

NCT ID: NCT06231264 Recruiting - Ulcerative Colitis Clinical Trials

Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative Colitis

Start date: January 19, 2024
Phase: N/A
Study type: Interventional

The aim of this study was to evaluate the efficacy and safety of transcutaneous electrical acustimulation in patients with mild to moderate ulcerative colitis.

NCT ID: NCT06214078 Recruiting - Clinical trials for Ulcerative Colitis Chronic Mild

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the safety and efficacy of nicotinamide mononucleotide (NMN) and placebo in patients with mild ulcerative colitis (UC). The main question it aims to answer is Whether NMN can alleviate the intestinal pathology of UC patients, so as to play a role in UC treatment or adjuvant therapy. Participants will be randomized into two groups, an NMN group or a placebo group. Patients in the NMN group were treated with NMN intervention for 8 weeks. The placebo group received a placebo intervention for 8 weeks.

NCT ID: NCT06208982 Recruiting - Clinical trials for Computer-aided System

A Computer-aided (CADx)System in Real-time Characterization of Colorectal Ulcerative Diseases

Start date: June 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to construct and validate a Computer-aided (CADx)System in Real-time Characterization of Colorectal Ulcrerative Diseases. The main question it aims to answer are to demonstrate whether the newly developed CADx system has a high-level diagnostic accuracy in predicting characterization of colorectal ulcerative diseases. It is a multi-center, retrospective study. The study retrospectively collected colonoscopy images and videos of colorectal ulcers (including colorectal cancer, Crohn's disease, Ulcerative colitis, Intestinal tuberculosis and ischemic enteritis). A training cohort will be developed from majority of the included cases, followed by a validation cohort with the remaining cases. A CADx system in real-time characterization of colonic ulcer diseases was constructed using artificial intelligence to extract endoscopic features from the training set. Subsequently, the performance of the CADx system was preliminarily tested through the validation set.

NCT ID: NCT06183086 Recruiting - Pressure Ulcer Clinical Trials

PMCF Study on the Safety of Linovera® for the Treatment of Category-I Pressure Ulcers/Injuries

TRELINOIL
Start date: November 14, 2023
Phase:
Study type: Observational

To assess the safety and performance of Linovera® in the treatment of Category- I pressure ulcers/injuries.

NCT ID: NCT06181708 Recruiting - Venous Leg Ulcer Clinical Trials

Diagnostics in the Leg Ulcer Pathway

Start date: November 13, 2023
Phase:
Study type: Observational

This project aims to investigate 'The minimum diagnostic requirements for patients presenting to primary care with suspected venous ulcers.' In order to do this, the investigators intend to run a series of questionnaires with primary care services, vascular science services, and perform some cost effectiveness modelling on running diagnostic services in primary care and in secondary care settings. A one off questionnaire, designed in Qualtrics, will be sent out to primary care practitioners via social media and email contacts. This will be aimed at establishing their current role and any guidelines they follow with regards to the diagnosis and management of venous leg ulcers in primary care, and to determine their opinion of what this patient pathway should involve. A Delphi consensus will be carried out amongst vascular scientists across the UK to determine current and streamline future practice in diagnostics for patients with venous leg ulcers. The consensus will be achieved when there is ≥ 70% agreement. Cost effectiveness modelling will be carried out on two different scenarios of managing this cohort of patients, one in primary care and one in secondary care settings. Descriptive statistics will be performed on the results.